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Since the demonstration of the viral etiology of herpes simplex,
there has, naturally, been considerable interest in the immune
responses to this virus and particularly the abifity of serum ob-
tained from humans and animals, exposed to herpes, to neutral-
ize a known virus.
The purpose of this study was to treat patients suffering from
recurrent herpes simplex with a formalin inactivated herpes virus
and to study quantitatively the antibody response (i.e. the neu-
tralizing titre of the blood-serum) to these injections and, also,
to natural infection.
It is a well established fact that rabbits and guinea pigs that
have recovered from experimental herpetic infection show a
degree of immunity roughly parallel to the neutralizing property
of the serum, i.e. hyperimmunized animals, showing higher titres
in their sera, remain immune longer and resist higher concentra-
tions of virulent virus.
This is in marked contrast to man, where the unusual circum-
stance is found of a viral infection recurring with undiminished
virulence in spite of neutralizing antibodies in the sera. Erup-
tions frequently—in fact, usually—recur at or near the same site,
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indicating that no local immunity is produced. Quantitative
studies of the antibody titre in relation to recurring attacks have
not been made. Many investigators have studied the incidence
of neutralizing antibodies in the sera of "normal" persons and
those with herpes. Gay and Holden (1) found specific neu-
tralizing antibodies in the sera of four out of nine individuals with
occasional attacks of herpes, and five out of seven with recurrent
herpes. Andrewes and Carmichael (2), (1930) observed these
antibodies in the sera of each of seven cases of recurrent herpes
and in 75 per cent of controls. Zinsser and Tang (3) found that
58.8 per cent of sera from normal adults and 43 per cent from
children contained this protective substance. Weyer (4) has
shown a correlation between age and the development of the
antibody: 0—5 years, 14 per cent; 20—25, 90 per cent; over 45,
54 per cent. Hudson, Cook and Adair (5) were unable to show
any appreciable alteration in incidence of neutralizing antibodies
in relation to sex, pregnancy or menses.
In reference to the treatment of recurrent herpes simplex,
Gildermeister and Herzberg in 1925 (6) and 1927 (7) reported
that there was a partial cross immunity between the viruses of
herpes and vaccinia. However, this observation was counter to
the experience of the earlier workers with these two viruses.
Bedson and Bland (8), and others, were unable to confirm the
observations of Gildermeister and Herzberg, and it is generally
conceded today, that there is no such relationship between these
two viruses. The observations of Rivers (9), that skin which has
just reacted tends to be less reactive, must be kept in mind; for
example, measles prevents the appearance of a Dick test. This
might be an explanation for Gildermeister and Herzberg's find-
ings. However, in 1928, Freund (10) treated seven cases of re-
current herpes with two vaccinia inoculations and reported clini-
cal freedom from recurrences. Minami and Ohmichi (11),
using a single inoculation of vaccinia in 10 patients reported
satisfactory results in all of them. In 1934 Wise and Sulzberger
(12a) reported satisfactory results with repeated vaccinations
in some but by no means in all their cases of recurrent herpes
treated by this method. Recently, Foster and Abshier (12b),
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using 2 to 6 vaccinia inoculations in patients with recurrent herpes,
reported their results on 35 patients followed over a period of two
years. Of these 35 patients only 5 had recurrences. R. T. Brain
(13) in discussing the apparent clinical results obtainable in treat-
ing recurrent herpes simplex with small pox vaccination expresses
the concept that this effect is "non-specific." Foster and Ab-
shier take exception to this concept and feel that there is a group
immunity phenomenon involved.
FORMOLIZED HERPES VIRUS USED THERAPEUTICALLY
Several workers have attempted to approach the problem of
treating these troublesome cases of recurrent herpes with a more
direct method. The herpes virus can be communicated to both
the rabbit and guinea pig, as well as to other animals, with facil-
ity. Hence various clinical attempts have been made to use
preparations derived from animal tissues infected with the virus,
treated with phenol, formalin, or heat, in such a way that the
virus can be termed "killed," i.e. the treated material could no
longer infect a susceptible animal. Holden (14), working with
rabbits, and Bedson (15), with guinea pigs, have been able to
produce immunity by means of a formalin-treated virus.
Martin and Caneja in 1933 (16) used a phenol-killed brain
emulsion intradermally in five cases of recurrent herpes of the
cornea. Two of these cases appeared to respond to this therapy
and experienced cessation of recurrences after the eighth and
seventeenth injection, respectively.
Biberstein and Jessner, in 1935 (17), used a 10 per cent heat-
killed emulsion of infected rabbit brain. Two-tenths of a cubic
centimeter of this material was injected intradermally twice
weekly for several weeks. Of eleven patients treated with re-
current herpes simplex nine showed some therapeutic effect, i.e.,
a definite lengthening of interval between attacks and a decrease
in severity of these attacks. These authors also observed in
some of their cases a displacement of the lesions to a new site, a
focal reaction following the first injection, and herpetic-like re-
actions at the site of the intradermal inoculations (Isomorpher
Reizeffect of Koebner?).
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R. T. Brain (13) in 1936 reported five cases of recurrent herpes
treated with a ten per cent suspension of infected guinea pig pads
inactivated with formalin. Each patient received weekly sub-
cutaneous injections of 0.5 cc. to 1 cc. over a period of one to
seven weeks (maximum given to any one patient was 7.1 cc.).
Brain also found an increase in interval and decrease in severity
of the attacks in the treated patients.
Merrill (18) has pointed out that there is a definite relation-
ship between the size and number of antigenic particles necessary
to produce demonstrable immunological reactions, and has sug-
gested that this mass-factor be considered in immunologic studies
on virus.
It was, therefore, desirable to follow the effects of large doses of
a formolized herpes virus given over a long period of time. This
work was started in February 1936. During this period 14 cases
were followed. Every care was taken in the selection of patients
used in this series. Only patients who had attacks at regular
rhythmic intervals were selected, i.e. at least one attack in eight
weeks. Every effort was made to ascertain the frequency of
attacks before treatment was instituted, inasmuch as, ordinarily,
patients are apt to be unreliable as to the frequency of attacks.
In the cases where the lesions or location were not typical of
herpes simplex, inoculation of a rabbit's cornea (Gruter's test)
was done, and immunologic study of the inoculated rabbits was
performed (i.e. demonstration of the appearance of the herpes
neutralizing substance in the infected animals' blood serum; or
if the animal developed an encephalitis, neutralization of the
virus-containing brain tissue with a known herpes immune serum,
the virus and immune serum being combined and inoculated
intradermally in a susceptible rabbit).
The material2 used in this study was prepared as follows: The entire brain of a
rabbit dying of herpetic encephalitis' was macerated with 75 cc. of saline, con-
taining 0.055 cc. of formalin and kept in the refrigerator for two days. Then 1.8
2 This material was prepared under the supervision of Dr. M. Holden of the
Department of Bacteriology, Columbia University.
'The E. L. 1 strain was used. This strain was originally isolated by Perdeau
from a patient with epidemic encephalitis.
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cc. of tricresol was added as a preservative to this mixture, and the heavy particles
removed by centrifugation. The remaining material was then tested for bacterial
sterility and for viable virus by injecting 0.4 cc. into a rabbit intracerebrally.
The following method was used in treating the patients. First, 0.1 cc. of a
1:10 saline dilution of the formolized herpes virus material was injected intra-
dermally, with a saline control, and observed for any immediate wheal and
pseudopod formation 15 minutes later. It is of interest to note that none of the
patients treated showed any immediate reaction to this material. On the same
day, the patient received 0.5 cc. of the formolized herpes virus material subcu-
taneously. Injections were given at weekly intervals alternately in the right and
left arms. On the second week 1.0 cc, of the material was given subcutaneously.
On the third week 1.5 cc. was given intramuscularly, and on subsequent weeks
the dose was increased by 0.5 cc. until a maintenance dosage of 3.0 or 4.0 cc.
given intramuscularly was reached. This level of dosage was maintained. In-
jections were continued until a total of 30 to 50 cc. of the formolized herpes virus
was given.
Immediately following the injection the patients experienced, at the injection
site, moderate pain lasting about five minutes. Some of the patients reported
a slight stiffness in the extremity which had received the injection. This lasted
about 24 hours. None of the patients had any systemic reaction following the
injection.
From table I it can be observed that only one case of the four-
teen patients observed failed to show any response to the formo-
lized herpes virus therapy. It must also be noted that none of
the fourteen cases treated showed a complete cessation of her-
petic attacks. Three of the patients treated experienced oniy
one outbreak in the year's treatment; and the remaining eleven
all showed a marked reduction of the number of attacks. In
many of the patients observed, previous to therapy, the duration
of each outbreak had extended over a period of two or three
weeks. This was due to the fact that these patients would have
continuous fresh outbreaks of vesicles during this period instead
of the usual initial outburst and then resolution ordinarily seen
in herpes simplex. Of greatest importance is the marked de-
crease in the duration of the individual attacks following therapy.
Most of these attacks would be distinctly abortive and be char-
acterized by one, two or three isolated vesicles, instead of the
usual cluster followed by more and more vesicles such as these
patients had been experiencing. These isolated vesicles would
dry in two to forty-eight hours and the crusts would be gone in
two to four days. This phenomenon is rarely seen in untreated
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herpes simplex and would indicate a definite effect obtained from
this material.
It is also of considerable interest that, at the onset of therapy,
eight of the fifteen patients treated showed recurrences usually
at the time that the next outbreak was to be expected. These
outbreaks were markedly reduced in severity and duration, us-
ually lasting only one or two days and can be characterized as
abortive attacks. This observation also seems to indicate the
efficacy of the formolized herpes material.
Five of the patients in this series have been observed for more
than two years following the onset of the formolized herpes virus
therapy. All of these cases, 1, 2, 3, 4 and 6, have shown the same
decrease in frequency and duration of attacks in the second year
following therapy as they did in the first year.
THE HERPES NEUTRALIZING SUBSTANCE
It was the purpose of this study to observe what changes occur
in the neutralizing power of blood sera collected from individuals
under various circumstances. Quantitative studies were made
of the neutralizing titre of (1) sera taken both during and at var-
ious intervals between attacks, (2) sera from patients with re-
current herpes, before, during and after therapy with the formo-
lized herpes virus material and (3) sera from individuals who, as
far as they could recall, had never had herpes, as compared with
sera collected from individuals who had histories of herpes.
The following method of determination of neutralizing titre was used: The
E. L. 1 herpes strain was used. Since this strain is maintained by monthly
passage through rabbit brains, it loses its dermatropic property. Rapid passage
through rabbit testes, however, brings a return of the dermatropic characteristic.
Once this "skin strain" was obtained, the next step was to dilute with saline the
serum or the series of sera to be studied. In addition to the undiluted sera, the
dilutions used were 1:10, 1:20, 1:40 and 1:80. The next step was to make an
emulsion of the testicular virus-containing tissue, this emulsion consisting of
one part testicular material and five parts of physiological saline. The emulsion
was centrifuged and the supernatant material drawn off. Aliquot parts of this
supernatant material was mixed with an equal amount of serum dilution and
placed in the incubator at 37.00 centigrade for one hour. At the end of this time
0.2 cc. of each mixture was injected intradermally into the shaved skins of two
rabbits. If the serum dilution used neutralized the virus, no reaction would
appear on the rabbit's skin. However, if the serum dilution failed to neutralize,
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a characteristic herpetic cluster would appear on the rabbit's skin. On each
animal used, two controls were run, consisting of equal parts of (1) normal rabbit
serum and virus, and (2) of known herpes-immune rabbit's serum and virus.
Since rabbits vary in their reactivity to herpes virus, and since the virus itself
varied in virulence from passage to passage, in order to make comparative studies,
it was obviously necessary to run a complete series of sera on the same rabbit.
FIG. 1. NEUTRALIZATION TESTs ON RABBITS SKIN, ILLUSTRATING TYPE OF REAc-
TION OBTAINED. INJECTION OF MIXTURE CONTAINING TESTIcULAR RERPETIC
VIRUS AND VARIOUS DILUTIONS OF PATIENT'S SERUM
Reading from left to right those reactions not covered by redundant hair.
Top row: (1) Unneutralized mixture, 0.1 cc. virus plus 0.1 cc. of 1:10 serum
dilution. (2) Unneutralized mixture, 0.1 cc. virus plus 0.1 cc. of 1:20 serum dilu-
tion. (3) Unneutralized mixture, 0.1 cc. virus plus 0.1 cc. of 1:40 serum dilution.(4) Unneutralized mixture, 0.1 cc. virus plus 0.1 cc. of 1:80 serum dilution. (5)
Neutralized mixture, 0.1 cc. virus plus 0.1 cc. of undiluted serum.
Lower row: (1) Unneutralized mixture, 0.1 cc. virus plus 0.1 cc. of 1:10 serum
dilution. (2) Unneutralized mixture, 0.1 cc. virus plus 0.1 cc. of 1:20 serum dilu-
tion. (3) Unneutralized mixture, 0.1 cc. virus plus 0.1 cc. of 1:40 serum dilution.(4) Unneutralized mixture, 0.1 cc. virus plus 0.1 cc. of 1:80 serum dilution. (5)
Neutralized mixture, 0.1 cc. virus plus 0.1 cc. of undiluted serum.
This made it unavoidable, in some instances to preserve serum for several months,
until an entire series of blood specimens was collected from the same patient.
Consequently all tubes containing serum were stoppered with a cotton plug and
cork, and the ends of the tubes were then paraffinized. These tubes were kept
in the refrigerator and any tube that showed bacterial contamination was dis-
carded.
Phose 1. A series of blood sera collected from 5 individuals before, during,
- 4': .,'ts,
*
S. J.
":'
S.
£
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following and between attacks of herpes simplex was tested to determine what
change took place in the neutralizing titre of the serum at these various times.
Using the method as outlined above, every series of sera showed the same re-
sults as illustrated in table II.
Of the four remaining series studied, blood sera were collected at the following
time in relation to the attacks of herpes.
Case A. S. 5/25/36 (7-day-old attack), 6/8/36 (21 days following the onset
of the last attack and 102 days preceding a subsequent attack) and 9/18/36 (3-day-
old attack).
Case T. M. 12/5/36 (1-day-old attack), 12/14/36 (10 days following onset of
an attack), and 12/22/36 (18 days following an attack).
Case N. V. 7/23/36 (1-day-old attack), 7/29/36 (7 days following onset of an
attack, and 12 days preceding a subsequent attack) and 8/10/36 (7 days after
onset of an attack).
TABLE II
Studies on serum of patient A. V.
SERUM DILUTION
j:1
0
1:10
0
1:20
+
1:40
++
-
1:80
++6/ 3/26 (attack 2 days old)
8/ 9/36 (attack 2 days old) 0 0 + ++ +
7/14/36 (35 days from last attack) 0 0 + ++ ++
7/21/36 (attack 1 day old) 0 0 ++ --+ ++
* 0.1 cc. of each dilution of serum mixed and incubated for one hour with 0.1 cc.
of 1:8 dilution of testicular herpes virus.
+ indicates failure of the serum to neutralize the virus and a consequent ap-
pearance of a lesion on the rabbit's skin. The number of +'s indicates the sever-
ity of the lesion.
0 indicates complete neutralization and no lesions.
Case J. R. 4/7/36 (1-day-old attack), 4/28/36 (15 days following onset of an
attack) and 5/12/36 (39 days following an attack).
Three of these five series were repeated at three different times and the same
general type of results was obtained.
From the above it can be noted that blood sera were collected
on the first, second, third and seventh day of a herpes attack; on
the 10th, 15th, 18th, 21st, 35th and 39th day following an attack;
and on the 7th, 12th, and 102nd day previous to an attack. In
no instance could a change in titre be detected in relation to the
appearance of eruptions, and therefore the neutralizing titre can-
not be considered a criterion of clinical immunity.
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Phase 2. A series of blood sera was collected from four patients with recur-
rent herpes simplex, who had all received the formolized herpes virus therapy,
and who had all experienced an apparent clinical improvement of their condition.
Using the same method of titrating the neutralizing substance as previously
explained, in all four instances, the same type of results were obtained as illus-
trated in table III.
In all instances one or two samples were collected before and after the patient
had received the formolized herpes virus, and were tested together with sera
collected during the period of receiving this material.
Two of these four patients (W. C. and N. J.) bad experienced
only one attack in the interval during which blood samples were
collected (approximately 7 and 9 months respectively), whereas
TABLE III
Patient W. C.
SERUM DILUTION
*1:1 1:10 1:20 1:40 1:80
2/25/36 0 0 0 + ++
3/11/36 0 0 0 + ++
3/30/36 0 0 0 + ++
4/20/36 0 0 0 + ++
7/11/36 0 0 0 + ++
9/18/36 0 0 0 -- ++
* 0.1 cc. of each dilution of serum mixed and incubated for one hour with 0.1 cc.
of 1:6 dilution of testicular herpes virus. Treatment continued from 2/26/36
through June 15, 1936.
previous to this period W. C.'s and N. J.'s attacks were at a 4—6
week interval.
Of the remaining two, L. M. experienced seven attacks in the
interval tested, and G. B. had four attacks, (during approxi-
mately 11 and 12 months respectively). However, in both of
these cases, this was a marked decrease in the number of attacks
as compared with a similar period immediately preceding.
It would seem therefore, that in spite of apparent clinical
improvement during the period studied, there was no change in
neutralizing titre in the blood serum of the four patients ob-
served. This would also indicate that the neutralizing titre can-
not be considered as an index of clinical immunity in herpes
simplex.
FORMOLIZED HERPES VIRUS THERAPY 2'??
Phase 3. Samples of blood were collected from six individuals who gave a
history of never having had herpes, and from 22 individuals known to have suf-
fered from herpes. The blood samples from the non-herpetics were collected
from as reliable source as possible to obtain, 2 physicians, 2 technicians and 2
nurses. The bloods were titrated in the same way as in the previous two phases,
namely against a known virus, and were inoculated intradermally on the same
rabbit's skin.
Of the six blood sera obtained from the non-herpetics, three showed complete
absence of neutralizing substances, and three showed a neutralizing titre of 1:20
(i.e. the 1:40 titre of serum was not adequate to prevent herpetic lesions from
appearing on the rabbit's skin). All of the 22 sera obtained from the herpetics
had this neutralizing property. Ten of these sera were tested undiluted. Of the
remaining 12, six had a neutralizing titre of 1:20 and six of 1:40.
This would seem to imply, assuming the history of not having
had herpes to be reliable, that three of these non-herpetics had
never been infected by the herpes virus, and that the other three
having been exposed, have shown an immune response without
having an apparent lesion. However, it must be kept in mind
that these individuals might have had hidden or unrecognizable
lesions, or mouth lesions that they did not interpret as being
herpetic.
It is also interesting to note that these six blood sera from in-
dividuals who have not had herpes were titrated concomitantly
with a sample collected from a patient with recurrent herpes
simplex. The latter also had the same neutralizing titre (1:20).
All of these observations would seem to indicate the inade-
quacy of the neutralizing titre as an index of clinical immunity.
It has been shown by many workers that the neutralizing sub-
stance appears in the guinea pig and rabbit only after exposure
to the herpes virus (Flexner and Amoss (19), McKinley and
Holden (20). However, this neutralizing property of the blood
serum in humans cannot be considered as a criterion of clinical
immunity.
It would seem that the neutralizing substance appears in the
blood stream following exposure to the virus, but reaches an ap-
parently stationary level which does not fluctuate, regardless of
the clinical state in relation to attacks of herpes or clinical free-
dom. This would also seem to indicate that clinical immunity
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to herpes simplex might not be a systemic phenomenon but
rather a local one; and that other factors cOme into play, as to
the nature of which we have no concept today.
As far as a more effective therapeutic approach to this problem
is concerned, it is still possible that a more purified virus might
be capable of raising the neutralizing titre of the blood to a level
at which outbreaks will not occur.
SUMMARY
1. Fourteen patients with recurrent herpes simplex were
treated with a formalin-treated herpes-infected-brain emulsion.
Thirteen showed an increase in interval between attacks and a
decrease of severity of the individual attacks. However, none
of these patients experienced a complete remission. The re-
currences following therapy were abortive and were character-
ized by the appearance of one, two, or three vesicles, which would
dry in twenty-four to forty-eight hours, the crusts being gone in
two to four days, a course not usually seen in untreated herpes
simplex. This observation and the increase in interval noted
would indicate the effectiveness of the formolized herpes virus
material used.
2. Blood sera were collected from five patients with herpes
simplex, before, during, following and between attacks and no
change in neutralizing titre was noted at these different times.
3. Samples of blood collected from four patients who received
formolized herpes virus were tested and showed no change in
neutralizing titre in spite of clinical improvement experienced by
these patients.
4. Blood samples from six individuals who never had herpes
were studied for neutralizing titre. Three showed the presence
of the neutralizing substance and three did not. In contrast to
this, the sera collected from 22 patients who had had herpes, all
possessed this neutralizing property.
5. The observations made seem to indicate that the presence
or titre of neutralizing substance while the result of exposure
to the virus is not a measure of clinical immunity.
580 Fifth Avenue
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DISCUSSION
Dn. SAMUEL M. PECK, New York City: This paper was most interesting, and
I hope that it will lead us to an efficacious form of therapy in this rather stubborn
condition. I would like to know in the light of the experiments just presented,
how one would explain the effectiveness of the old method of treatment by the
use of vaccine virus. I thought in some of my cases that my results were quite
comparable to those presented by Dr. Frank. I would like to know if the blood
serum of patients treated with ordinary vaccine virus contained an increased titer
of antibodies in the blood serum, as he has shown with his formolized virus ther-
apy. There might possibly be another explanation for these results by the theory
of local tissue immunity according to the ideas of Besredka.
Dn. GEORGE C. AtnREws, New York City: I have been in touch with the work
of Dr. Abahier in immunizing with smallpox virus against herpes simplex, and
certain clinical features stand out as very interesting. Of course the results are
not uniform. The period of freedom from attacks varies in different patients.
Some patients are completely free for several years. Others have a series of six
or eight weekly vaccinations and their period of freedom is only three or four
months. However, in some cases, one does get splendid results. The number of
vaccinations that should be given to any one case is always a matter of conjecture.
I think that formerly six were recommended but now we feel that one should give
ten or twelve. It seems that the more vaccinations you give, the better the re-
sults. Clinically often there is an immediate improvement in the lesion; that is,
if a person comes in with a large herpes lesion, a patient who has had many at-
tacks and each one usually takes several weeks to disappear, there is a definite
improvement in the lesion a few days after the vaccination. It seems to be of
immediate local benefit. In repeated vaccinations I have been impressed by the
fact that there is nearly always a local reaction where you vaccinate, if it is care-
fully watched. Even though there is no vesicle or pustule formed, there will be a
little local redness, or itching, coming on about the fifth day, and I believe there
will be a change in the immunity in spite of the fact that there will not be a well
marked local reaction.
DR. JOHN H. SvOKES, Philadelphia, Pa.: I would like to ask whether any at-
tempt was made to develop a local immunity at the expected site of occurrence
of the lesion by injecting the formolized virus at the expected site; also, whether
any study was made of the comparative effect of intradermal as compared to
subcutaneous use of the formolized virus. Perhaps formolized virus cannot be
injected intradermally. I do not know, and I should like to know.
DR. MARION B. SULZBERGER, New York City: As far as the practical aspects
of this work are concerned, I think that I have now treated enough cases, some
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with vaccination with the variola virus and others with the formolized herpes
virus, to say that both methods have had signal successes and signal failures.
However, the number of my cases is not sufficiently large to allow me to compare
the relative practical merits of the two methods. Nevertheless, one can perhaps
compare them from the theoretical viewpoint. One method uses the living van-
ola virus, from the standpoint of non-specific effect of one living virus upon
infection with another. This method has the disadvantage of being non-specific
and the advantage of using a living virus. In the other method, that of Dr.
Frank, one is employing the specific virus but it is non-living, it is dead. And
so far there is no evidence to show that dead virus regularly confers immunity.
In other words, we are not able, for example, to vaccinate against smallpox
with non-living, dead smallpox virus. It would surely be a great advance if
we could. There is another important theoretical and basic concept embodied in
Dr. Frank's work. This is that the clinical immunity or susceptibility of the skin
does not necessarily go parallel with the blood titre of immune bodies. I believe
that this statement may apply not only to virus diseases but to others as well.
In this connection I may state that we have adequate evidence both from the
literature and our own experiments that the immunity or susceptibility of
the skin to staphylococcus toxin does not necessarily run parallel with the titre
of anti-toxic units in the blood serum. (Suizberger and Rubin: Discussion to
Tannenbaum, Joyner, Speed and Bremer, J. Allergy, 9: 241, 1938.)
Dx. D. C. SMITH, University of Virginia: The development of the ultra centri-
fuge and its use in the separation and purification of virus proteins will undoubt-
edly lead to improved methods for this study. It may well be that a virus vaccine
prepared with the addition of formalin is ineffective because of chemical changes
produced.
Dx. GEORGE S. WILLI&,.asoN, Ottawa, Canada: I would like to ask any of the
members, or Dr. Frank, if they have attempted to use blister fluid for local inocu-
lations, and if so, with what result? I have employed this procedure in a small
group of patients with apparently encouraging results, but was unable to arrive
at definite conclusions from this small group.
Dx. SAMUEL M. KAUFMAN, New York City: I would like to know how Dr.
Frank interprets the improvement in cases of herpes simplex by the treatment of
fractional doses of roentgen rays and the diminished recurrences.
Dx. GEORGE SCHWARTZ, Boston, Mass.: I would like to ask Dr. Frank if he has
used controls with other non-specific substances, and whether, if he has, there
has occurred an increase or decrease in sensitivity. I wonder if the effect here is
specific or non-specific?
Dx. FRED D. WEIDMAN, Philadelphia, Pa.: I noticed in the table one out-
standing instance, a patient aged eighteen where the therapy was not effective.
I would like to ask if there were any data peculiar to that case which might throw
light on that situation?
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DR. I. L ARN5SON, Buffalo, New York: In using smallpox vaccine, the scratch
method is less effective than the intradermal.
DR. SAMUEL B. FEANR, New York City: I want to thank the discussers for their
contributions. It is believed today that there is no relationship between the
vaccinia and herpes virus. However, clinically we do see therapeutic results.
In discussion with others, several have made the observation that £hey get their
best clinical effect when a take is obtained with vaccinia. Perhaps the vaccinia
reaction makes the skin less reactive to an attack of herpes, as seen in the rela-
tionship of measles to the Dick test.
In answer to Dr. Stokes, I made no attempt to inject the material at the site
where the recurrence was usually found. I was mainly interested in seeing what
large amounts of the material would do, rather than in the intradermal inocu-
lation.
I have tried inoculation of blister fluid from a herpetic lesion to another area
several times and have not obtained a successful take. In contrast, I've been
able to get a take on myself with no difficulty. However, I rarely have herpes
and did not have one at the time. Perhaps the failure to get homologous takes
may be explained by a skin immunity that makes it resistant to an inoculation
during an attack.
I have not used any other protein or foreign substance in treating patients.
It is possible that the clinical effect of x-ray preventing recurrences of herpes
in some cases may be explained by some alteration of the virus, assuming the virus
remains latent in that area, or a change in the tissues making it unfavorable to
the virus.
In answer to Dr. Weidman, I have no explanation for the failure to get a
clinical effect in the patient he refers to.
